MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

Virginia governor Glenn Youngkin noted that MSD’s $3bn commitment to the state marks a “giant leap forward for Virginia’s life sciences sector”. Image credit: rarrarorro via Shutterstock.com. Merck & ...

Merck & Co (MSD) has broken ground on its new pharmaceutical manufacturing Centre of Excellence in Virginia, US, amid looming tariff threats from the Trump administration. The $3bn site, which is ...

MSD's booth is seen during an expo in Shanghai in November. [PHOTO/CHINA DAILY] With a long-term commitment to the Chinese market, United States-based global pharmaceutical company MSD plans to ...

RIYADH, Saudi Arabia: Lifera, a PIF Company, announces the signing of a non-binding Memorandum of Understanding (MOU) with MSD (also known as Merck & Co., Inc., Rahway, N.J., USA in the U.S. and ...

Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated at ...